Health Canada Investigates Gilenya

Health Canada has announced that it will investigate the multiple sclerosis drug Gilenya (fingolimod) after learning of serious adverse events it can cause, including death.

There have been 11 deaths reported internationally so far that have been linked to Gilenya use, three of which involved heart attacks. One of the incidences involved a disturbance of the heart’s rhythm while the other seven remained unexplained, Health Canada reported. One of the patients whose death was unexplained died within 24 hours of taking a dose of Gilenya.

There have been no deaths reported in Canada.

This investigation comes approximately one month after health regulators from the U.S. and Europe decided to review the drug.

If you or a loved one has been harmed by a dangerous drug, contact Sokolove Law for a free legal consultation and to find out if you have grounds to pursue legal action.

Tags:

About Us

Sokolove Law, LLC is the nation’s largest marketer of legal services that help people obtain access to the civil justice system while ensuring they receive superior quality legal representation. With over 30 years of service, Sokolove Law has helped thousands of injured parties obtain the compensation they deserve from their legal claim such as mesothelioma, cerebral palsy, nursing home abuse, dangerous drugs, disability insurance denial, and medical malpractice cases.

Subscribe

Quick facts

For legal help, call (877) 490-6520
Tweet this